⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7744684 | 0.77 | — | — | |
| SCHEMBL23735607 | 0.74 | — | — | |
| SCHEMBL24624621 | 0.72 | DNM1 (0.50) | — | |
| SCHEMBL11989335 | 0.70 | — | — | |
| SCHEMBL17875025 | 0.67 | — | — | |
| Ethylenediamine SCHEMBL10884255 | 0.66 | — | — | |
| Ethylenediamine SCHEMBL37647 | 0.65 | — | — | |
| Ethylenediamine SCHEMBL3083 | 0.65 | — | — | |
| Ethylenediamine SCHEMBL28924405 | 0.65 | NFKB1 (0.50) | — | |
| Ethylenediamine SCHEMBL7085968 | 0.65 | NFKB1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083900-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A DRUG MOIETY | TUBULIS GMBH (DE) | 2023-05-19 | — | — | WO | disclosed |
| US-20170119896-A1 | TERMINALLY MODIFIED POLYMERS AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9585875-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2017-03-07 | — | — | US | disclosed |
| US-20140371276-A1 | TRPM8 ANTAGONISTS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2014-12-18 | — | — | US | disclosed |
| WO-2011060392-A1 | SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS | RECEPTOS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |